Summary and next episodes
Downloadable resources
Dr Aaron Lisberg was the lead author on one of two papers recently published on the prophylaxis, monitoring, and management of select datopotamab deruxtecan (Dato-DXd)-associated adverse events (AEs).
Watch this short video to hear Dr Lisberg focus on 3 key adverse events related to Dato-DXd, and explain how you can proactively monitor and manage these AEs to improve the treatment experience for your patients, and achieve optimal outcomes.
You can also view and download a series of infographics summarising the critical points for each adverse event, along with a helpful checklist to use when starting a patient on Dato-DXd.
Visit the publications for more details:
- Datopotamab deruxtecan-associated select adverse events: clinical practices and institutional protocols on prophylaxis, monitoring, and management. Lisberg A, et al. The Oncologist 2025; 30: oyaf225
- Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Meric-Bernstam F, et al. The Oncologist 2025; 30: oyaf031
Clinical takeaways
- Datopotamab deruxtecan (Dato-DXd) shows clinically meaningful activity in previously treated advanced solid tumours (including NSCLC and HR+/HER2– breast cancer)
- Mucositis/stomatitis, nausea, and ocular events are key, mostly low-grade toxicities, to be aware of
- Proactive prophylaxis across all AEs and education is critical
- Structured, multidisciplinary monitoring enables safe delivery, including early detection and management of uncommon but serious AEs such as interstitial lung disease (ILD)
Download all infographics 
Duration
Language(s)
Downloadable 
1 MIN
May 2026 
